Biotech · Public company · New York, NY, US
Actinium Pharmaceuticals, Inc.
Ticker ATNM · SEC CIK 0001388320
Track this companyFree. Adds Actinium Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials63 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline11
- Conventional CarePhase 3 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- HCTPhase 3 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Iomab-BPhase 3 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Cytarabine (Phase 1 only)Phase 2 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- Furosemide (Phase 1 only)Phase 2 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- Lintuzumab-Ac225Phase 2 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- Lintuzumab-Ac225Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- SpironolactonePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- SpironolactonePhase 2 · AMLClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Lintuzumab AC 225Phase 1 · Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)PHASE1 · RECRUITING · started Apr 28, 2025ClinicalTrials.gov NCT07015684 · fetched Nov 12, 2026
- IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCLPHASE1_PHASE2 · RECRUITING · started Apr 25, 2025ClinicalTrials.gov NCT06768905 · fetched Nov 12, 2026
- Venetoclax and Lintuzumab-Ac225 in AML PatientsPHASE1_PHASE2 · UNKNOWN · started Jan 15, 2020ClinicalTrials.gov NCT03867682 · fetched Nov 12, 2026
- A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple MyelomaPHASE1 · TERMINATED · started Dec 1, 2016ClinicalTrials.gov NCT02998047 · fetched Nov 12, 2026
- Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid LeukemiaPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 1, 2016ClinicalTrials.gov NCT02665065 · fetched Nov 12, 2026
- Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) PatientsPHASE1_PHASE2 · COMPLETED · started Oct 1, 2012ClinicalTrials.gov NCT02575963 · fetched Nov 12, 2026
SEC filings12
- 8-K · CURRENT REPORTSEC EDGAR · filed Oct 15, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed Aug 7, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jun 18, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed May 29, 2026 · fetched Nov 12, 2026
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 10-K · ANNUAL REPORTSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026
- 8-K/A · AMENDMENT NO.1 TO FORM 8-KSEC EDGAR · filed Mar 26, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Feb 13, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Nov 26, 2025 · fetched Nov 12, 2026
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed Aug 8, 2025 · fetched Nov 12, 2026
NIH awards1
- Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCLFiscal year 2024 · $865.3KNIH RePORTER 5R42CA254685-03 · fetched Nov 12, 2026